The latest price target for Ayala Pharmaceuticals (OTCEM:ADXS) was reported by Ladenburg Thalmann on November 16, 2023. The analyst firm set a price target for $0.00 expecting ADXS to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Ayala Pharmaceuticals (OTCEM:ADXS) was provided by Ladenburg Thalmann, and Ayala Pharmaceuticals downgraded their neutral rating.

The last upgrade for Ayala Pharmaceuticals Inc happened on May 30, 2023 when Ladenburg Thalmann raised their price target to $4. Ladenburg Thalmann previously had a neutral for Ayala Pharmaceuticals Inc.

The last downgrade for Ayala Pharmaceuticals Inc happened on November 16, 2023 when Ladenburg Thalmann changed their price target from N/A to N/A for Ayala Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ayala Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ayala Pharmaceuticals was filed on November 16, 2023 so you should expect the next rating to be made available sometime around November 16, 2024.

While ratings are subjective and will change, the latest Ayala Pharmaceuticals (ADXS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Ayala Pharmaceuticals (ADXS) is trading at is $0.14, which is out of the analyst’s predicted range.